Increased expression of AXL receptor tyrosine kinase (AXL) has been observed in the samples of NSCLC patients resistant to EGFR, ALK, or RET TKIs treatment, indicating that AXL TKIs might be an alternative for combination therapy in targeted therapy for NSCLC.276, 277, 278. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.